Cost-effectiveness of acalabrutinib monotherapy or with obinutuzumab versus chemoimmunotherapy for untreated chronic lymphocytic leukemia in China
在中国,阿卡替尼单药治疗或联合奥妥珠单抗治疗与化疗免疫疗法治疗未经治疗的慢性淋巴细胞白血病相比的成本效益分析
期刊:Therapeutic Advances in Hematology
影响因子:3.1
doi:10.1177/20406207241295559
Li, Mengya; Zhong, Xiaoyan; Zhang, Chengbin; Luo, Hongli; Luo, Li; Huang, Yilan; Jiang, Longyang